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Background: Patients with cystic ﬁbrosis (CF) have increasing treatment complexity and high treatment burden. We describe trends in treatment
complexity and evaluate its relationship with health outcomes.
Methods: Using Epidemiologic Study of Cystic Fibrosis (ESCF) data, we developed a treatment complexity score (TCS) from 37 chronic therapies
and assessed change by age group (6–13, 14–17, and 18+ years) over a three year period. Differences in average site TCS were evaluated by
quartiles based on FEV1, BMI, or Treatment Burden score on the Cystic Fibrosis Questionnaire-Revised (CFQ-R).
Results: TCS scores were calculated for 7252 individual patients (42% child, 16% adolescent, 43% adult) across 153 sites. In 2003, mean TCS was
11.1 for children, 11.8 for adolescents, and 12.1 for adults. In all 3 age groups, TCS increased over 3 years; the increase in TCS from 2003–2005
for children was 1.25 (95% CI 1.16–1.34), for adolescents 0.77 (0.62–0.93), and for adults 1.20 (1.08–1.31) (all Pb0.001 for trend over time). At
the site level, there were no signiﬁcant differences in mean TCS based on FEV1 quartile. Mean TCS was higher in the highest BMI z-score quartile.
Across all 3 versions of the CFQ-R, mean TCS was lower at sites in the highest quartiles (lowest burden) for CFQ-R treatment burden scores.
Conclusion: Treatment complexity was highest among adults with CF, although over 3 years, we observed a signiﬁcant increase in treatment
complexity in all age groups. Such increases in treatment complexity pose a challenge to patient self-management and adherence. Future research
is needed to understand the associations between treatment complexity and subsequent health outcomes to reduce treatment burden and improve
disease management.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Over the past several decades, improvements in the manage-
ment of cystic fibrosis (CF) have led to significant increases in
patient survival and quality of life [1]. Treatment guidelines for⁎ Corresponding author at: Children's Hospital Boston, Division of Respiratory
Diseases, 300 Longwood Avenue, Boston,MA 02115, United States. Tel.: +1 617
355 6363.
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http://dx.doi.org/10.1016/j.jcf.2012.12.009lishedrespiratory medications in CF recommend a number of chronic
maintenance treatments, including bronchodilators, mucolytics,
inhaled antibiotics, anti-inflammatories, and airway hydrators
[2]. In addition, a vigorous airway clearance regimen and regular
exercise are recommended for most patients with CF [3]. This
treatment regimen is both time-consuming and complex, requiring
use of specific devices, such as inhalers or nebulizers, with
varying administration and cleaning times. Beyond pulmonary
care, most individuals with CF require additional therapies, such
as pancreatic enzyme replacement. As a result, the treatmentby Elsevier B.V. All rights reserved.
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regimen takes two to three hours per day for routine CF care [4].
Adherence to CF treatment regimens is often poor, generally 50%
or less to prescribed therapies [5–7]. The high treatment burden in
CF may impede efforts to improve adherence to daily therapies
and consistency among health care practitioners in the implemen-
tation of chronic care guidelines.
Published data on treatment burden in CF exists for adults
[4], but there is a paucity of evidence on whether a similar
treatment burden exists for children and adolescents. A recent
analysis of longitudinal data from the Epidemiologic Study of
Cystic Fibrosis (ESCF) showed that individuals of all ages with
increasing treatment complexity over a one year period had
worsening scores on a patient-reported outcome measure of
treatment burden [8]. With early diagnosis through newborn
screening and research documenting early signs of airway
inflammation and infection in younger children, earlier adoption
of chronic therapies is becoming a cornerstone of aggressive CF
care. Prior analyses of ESCF have also shown that more
aggressive care practices are associated with improved patient
outcomes [9]. Introducing complex and time-consuming thera-
pies early in life, and requiring maintenance of these regimens
through adulthood, poses significant challenges to individual
patient and family adherence.
The objectives of this study were 1) to evaluate CF treatment
complexity in individuals over time and as a function of age
and disease severity and 2) to describe differences in average
site-level CF treatment complexity and to determine whether
average treatment complexity was associated with site-specific
health outcomes including lung function, nutritional status, and
patient-reported treatment burden. We hypothesized that indi-
vidual treatment complexity would increase over time, and thatTable 1
Definition of treatment complexity score.
TCS Score=1 point TCS Score=2 points
Inhaled bronchodilator Hypertonic saline
Oral bronchodilator N-acetyl cysteine (Mucomyst
Inhaled corticosteroid Pancreatic enzymes
Oral corticosteroid Inhaled TOBI (once per day)
High dose ibuprofen Inhaled other aminoglycoside
Leukotriene inhibitor/antagonist Inhaled colistin (once per day
Cromolyn/mast cell stabilizer Other inhaled chronic suppre
Gastric acid suppressors Dornase alfa
Oral supplement
Ursodiol
Vitamins
Oral quinolone
Oral azithromycin (thrice weekly)
Other oral antibiotics
Antidepressants
Anxiolytics
Contraceptive/hormonal methods
Oral hypoglycemic
Pain medications (chronic)
Diureticsites with better patient outcomes would have higher average
treatment complexity.
2. Methods
2.1. Study population
ESCF is a large multicenter, longitudinal, prospective observa-
tional study of the clinical course of patients with CF in the United
States and Canada from 1994 through 2005 [10]. Data collected on
each patient included clinical demographics, signs and symptoms
of lung disease, results of spirometry and respiratory tract cultures,
and documented use of routine therapies. Quality of life data was
included in ESCF starting in 2003. Informed consent was obtained
according to decisions by a local or central human subjects review
board (Copernicus Group tracking number OVA1-03-008). For
this analysis, we used data from ESCF collected in 2003–2005.
Patients needed to be≥6 years in 2004 and have≥1 encounter in
2004 and ≥1 recorded pulmonary function test in 2004.
2.2. Outcome measures
The primary individual-level outcome assessed in this analysis
was a treatment complexity score (TCS), developed by assigning
a complexity of 1, 2, or 3 based on daily frequency, duration, and
ease of administration of each of 37 chronic therapies captured at
each ESCF encounter [8]. Oral medications and metered-dose
inhalers were assigned a TCS of 1 (n=20 therapies), once-
daily nebulized therapies and pancreatic enzymes a TCS of 2
(n=8 therapies), and airway clearance, twice-daily nebulized
therapies, use of oxygen, CPAP, BiPAP, and insulin or enteral
supplements a TCS of 3 (n=9 therapies). A composite TCS (rangeTCS Score=3 points
Airway clearance technique
) CPAP/BIPAP
Oxygen
Enteral supplement
(once per day) Parenteral supplement
) Inhaled TOBI (twice daily)
ssive antibiotic Inhaled other aminoglycoside (twice daily)
Inhaled colistin (twice daily)
Insulin
Table 2
Patient characteristics for TCS trends over time analysis.
N 7252
Characteristic Percentage
Age
6–13 41.7%
14–17 15.6%
≥18 42.7%
Male 52.3%
Genotype
Homozygous dF508 42.8%
Heterozygous dF508 32.1%
Other 8.8%
Unknown 16.4%
Non-Hispanic White 90.7%
FEV1
b40% predicted 8.4%
40%–b70% predicted 23.3%
70%–b100% predicted 41.0%
≥100% predicted 27.2%
Age-adjusted FEV1 decile
1st decile (lowest) 2.0%
2nd decile 3.6%
3rd decile 4.7%
4th decile 6.0%
5th decile 7.3%
6th decile 9.7%
7th decile 11.2%
8th decile 13.8%
9th decile 17.3%
10th decile (highest) 24.5%
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each encounter (Table 1). We further categorized therapies as
respiratory or non-respiratory (TCS-Respiratory and TCS-Other)
to develop specific subscores in these two domains.
Site-level health status outcomes included in the analyses
were: 1) lung function, measured by forced expiratory volume
in 1 s (FEV1) percent predicted (pulmonary function test results
were reported as measured values and converted to percent
predicted using reference equations fromWang et al. for females
through age 15 and males through age 17, and Hankinson et al. at
older ages) [11,12] and 2) nutritional status, measured by body
mass index (BMI) z-score. In addition, we assessed patient-
reported treatment burden as measured by the Treatment Burden
domain score from the Cystic Fibrosis Questionnaire-Revised
(CFQ-R; Quittner et al., in press), a validated CF-specific quality
of life instrument that includes teen/adult, parent, and child
versions [13,14]. Scores are standardized on a 0–100 point scale,
with higher scores indicating lower Treatment Burden. For the
site-level analyses, sites with fewer than 8 patients for any of the
outcomes were excluded.
2.3. Statistical analysis
We conducted two distinct analyses in this study. For the
first analysis, we evaluated trends in individual TCS scores
over time from 2003–2005. For this analysis, in addition to
requiring lung function and nutritional data in 2004 and ≥1
encounter, we also required data on these measures in each of
years 2003 and 2005. We examined changes in average TCS
over 3 years from 2003–2005 stratified by age [6–13 years
(child), 14–17 years (adolescent), 18+ years (adult)] and by lung
function decile [15]. Individuals who switched age groups across
years 2003–2005 were omitted from the trends over time
analyses. The minimum, median, and maximum TCS were
computed for each patient in each of years 2003, 2004, and 2005
and then averaged across patients for a given year. The analyses
were performed using the MIXED procedure in SAS treating
patient as a random effect, with ESTIMATE statements used to
test for differences between the extreme quartiles and for linear
trend across quartiles.
Our second analysis was a site-based analysis designed to
evaluate the relationship between average site TCS scores and
site-specific health outcomes. ESCF sites were stratified into
quartiles based on 2004 data for mean FEV1 (patient's best
value), mean BMI z-score (patient's mean), and mean CFQ-R
Treatment Burden score (patient's mean). Differences in average
TCS (based on patient's median value in 2004) among quartiles
were assessed using t-tests.
Statistical analyses were performed using SAS 9.2 (SAS
Institute, Inc., Cary, NC). A 2-sided P valueb .05 was considered
statistically significant.
3. Results
Over the 3 years of ESCF data collection, from 2003 to
2005, a total of 21,756 records, representing 7252 patients, had
an encounter-based TCS calculated in each year. Over this timeperiod, the mean TCS was 12.3±4.3 (inter-quartile range: 9.5–
15.0). The major determinants of the overall TCS were
respiratory therapies, as the mean TCS-Respiratory was 9.8±
3.4 (inter-quartile range: 8.0–12.0), and the mean TCS-Other
was 2.4±1.6 (inter-quartile range: 1.0–3.0). As expected there
was an inverse correlation between TCS and CFQ-R Treatment
Burden score which varied by age. For the adolescent (14–17)
and adult (18+) patients, the correlation was −0.27. For children
(age 6–13), the correlation for the child questionnaire was −0.10
and for the parent questionnaire was −0.32.
3.1. Trends over time analysis
A total of 7252 patients met inclusion criteria for the trends
over time analysis of TCS. Clinical and demographic character-
istics are shown in Table 2. In 2003, mean TCS (based on patient
median) was 11.1 for children, 11.8 for adolescents, and 12.1 for
adults. In all 3 age groups, TCS increased over 3 years; in 2005,
the mean TCS were 12.4, 12.6, and 13.3 respectively (all
Pb0.001 for trend over time). The mean increase in TCS from
2003 to 2005 for children was 1.25 (95% CI 1.16–1.34), for
adolescents 0.77 (0.62–0.93), and for adults 1.20 (1.08–1.31).
Mean TCS also increased in patients with more advanced lung
disease (Pb0.001 for trend over FEV1). Fig. 1 shows the mean
TCS for each year (2003–2005) stratified by age group and lung
function decile. Overall, the mean treatment complexity in all age
Fig. 1. Mean treatment complexity scores for each year by age group and age-adjusted FEV1 percent predicted decile. The test for trend for each decile in each age
group is statistically significant (Pb0.05) except for decile 5 for age 14–b18 (P=0.89). The statistical significance of differences between deciles varies somewhat by
age group. For age groups 6–13 years and ≥18 years, differences of 1.16 points or more are always significant (Pb0.05) and many differences as small as 0.5 points
are significant. For age group 14–17 years, most differences of 1.7 points or more are significant, but differences involving decile 1 may need to be as large as 2.5
points to be significant.
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deciles). The increase in TCS over the two years was particularly
pronounced among child and adolescent patients with more
advanced lung disease (Pb .001 for trend across deciles in TCS
increase for ages 6–13 and 18+; P=0.07 for age 14–17). Adults
with mild lung disease had the lowest overall mean TCS. These
trends were similar when the analyses were repeated on the two
components of TCS, TCS-Respiratory and TCS-Other.
3.2. Site-specific quartile analysis
Table 3 presents the mean FEV1 % predicted, BMI z-score,
and CFQ-R Treatment Burden scores in 2004 for the ESCF
sites included in the site-level analysis. Patient-level demo-
graphics for the highest and lowest quartile sites for Treatment
Burden among the three versions are shown in Table 4. For the
child (age 6–12 years) and parent (for children age 6–12 years)
CFQ-R, sites in the lowest quartile for Treatment Burden scores
(i.e. those with the highest perceived treatment burden) had
patients with lower mean lung function and a higher proportion
of Medicaid patients. By contrast, for the teen/adult CFQ-R
Treatment Burden quartiles, sites in the lowest quartile for
Treatment Burden, had patients with older mean age and lowerTable 3
Site-specific quartiles for FEV1 percent predicted, BMI Z-score, and treatment burd
Quartile FEV1 pct. pred. BMI Z-score
N Mean N Mean
Highest quartile 3467 89.9 3241 −0.05
3rd quartile 3328 83.6 2891 −0.27
2nd quartile 3583 75.7 3872 −0.46
Lowest quartile 2554 68.7 2833 −0.64
The quartile assessment was performed by age group within site, but is presented fo
switched age groups mid-year and met inclusion criteria for each age.mean lung function, with no significant difference in insurance
status.
Although no significant difference in mean TCS at the site
level were found based on FEV1% predicted quartiles, differences
in mean TCS based on the highest and lowest BMI z-score site
quartiles were statistically significant at b .05 (Fig. 2), indicating
that patients with better nutritional status had more complex
treatment regimens. In contrast, mean treatment complexity
scores were highest in sites that fell into the lowest quartile
(more treatment burden) across all three versions of the CFQ-R
Treatment Burden scale (Fig. 3). For example, in sites with the
lowest teen/adult CFQ-R Treatment Burden scores (i.e., highest
burden), mean TCS was 13.4 (95% CI 13.0, 13.8) compared with
a mean TCS of 12.5 (95% CI 12.1, 12.9) in the sites with the
best Treatment Burden scores (Pb .05). Statistical tests for trend
over quartiles mirrored the comparisons of the upper and lower
quartile.
4. Discussion
Recommended therapies for the chronic management of CF
result in a high treatment burden for individual patients. In this
study, we examined treatment complexity in a large observationalen scores (2004 data).
Treatment burden
(teen/adult)
Treatment burden
(parent)
Treatment burden
(child)
N Mean N Mean N Mean
699 68.4 334 72.9 231 77.0
742 63.6 499 65.8 334 72.2
501 59.5 280 59.7 319 67.6
478 54.0 191 54.1 207 61.3
r all age groups combined. Patients can be represented more than once if they
Table 4
Demographic comparisons between lowest and highest quartile sites for CFQ-R
treatment burden scores.
Teen/adult CFQ-R Lowest quartile
(N=447)
Highest quartile
(N=536)
P value a
Age, mean±SD 26.1±9.9 23.8±9.0 b .001
FEV1, mean±SD 67.9±24.2 71.9±25.8 .013
Female, n (%) 211 (47.2) 244 (45.5) .60
Non-Hispanic White, n (%) 413 (92.4) 511 (95.3) .053
Medicaid, n (%) 152 (34.3) 174 (32.9) .64
Parent CFQ-R Lowest quartile
(N=249)
Highest quartile
(N=327)
P value a
Age, mean±SD 9.1±2.0 9.2±2.0 .51
FEV1, mean±SD 94.1±19.7 98.3±19.7 .012
Female, n (%) 120 (48.2) 172 (52.6) .29
Non-Hispanic White, n (%) 232 (93.2) 295 (90.2) .21
Medicaid, n (%) 164 (66.1) 140 (43.5) b .001
Child CFQ-R Lowest quartile
(N=252)
Highest quartile
(N=254)
P value a
Age, mean±SD 9.2±2.0 9.3±2.0 .49
FEV1, mean±SD 94.8±19.1 100.3±20.3 .002
Female, n (%) 116 (46.0) 134 (52.8) .13
Non-Hispanic White, n (%) 198 (78.6) 233 (91.7) b .001
Medicaid, n (%) 169 (67.3) 108 (42.5) b .001
a P value obtained from chi square test statistic or Student's t-test, as
appropriate.
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treatment complexity was highest among adults and those with
more severe lung disease. However, over the 3-year analytic
period, treatment complexity increased in all age groups and
disease severity groups.
Our findings extend previous literature on treatment burden
in CF by examining a larger age spectrum and by comparing
treatment complexity scores to patient-reported burden. Based
on existing CF chronic care guidelines, an individual patientFig. 2. Treatment complexity scores by site-specific quartiles for FEV1 percent
predicted and BMI Z-score.would be expected to use at least 3–5 respiratory therapies,
along with 3–5 non-respiratory therapies each day [3]. In this
analysis we did not evaluate differences between an expected
treatment complexity based on care guidelines and the observed
treatment complexity, although future studies could consider
the impact of such differences on patient outcomes. Our results
suggest that patients, on average are prescribed a high intensity
regimen, with children being required to perform nearly as
many treatments as adults. Even in our short time window, we
observed a rise in complexity over time, with the increase in
complexity for children mirroring that of adolescents and
adults. When assessed by lung function severity, there was no
difference in treatment complexity based on age. Importantly,
during the time period we analyzed, no new therapies for CF
patients were introduced, indicating that these data reflect the
widespread adoption of an early, aggressive approach to care,
particularly for individuals with more severe disease.
The increase in treatment complexity over time across all
groups, regardless of disease severity, is statistically significant,
and likely has clinical significance as well. Although the
average rise in treatment complexity over the three year period
is small, a similarly sustained increase over a longer time period
would lead to substantial increases over the lifespan of a typical
CF patient. With increased recognition that early intervention
improves outcomes in CF, our observed trends likely reflect the
increased introduction of maintenance therapies across CF care
centers throughout the lifespan. Although such increases in
treatment complexity may be needed to improve overall
population health, on an individual level, they pose a challenge
to patient self-management, perceived treatment burden, and
adherence to chronic therapies. In our analysis, we have
identified inverse correlations between treatment complexity
scores and treatment burden scores. Interestingly, for younger
children, this correlation was of higher magnitude in the
parental questionnaires, suggesting that parents and children
may have differential perceptions of treatment burden. We
previously reported that changes in treatment complexity over a
12 month period in a subset of ESCF data were not associated
with changes in CFQ-R Treatment Burden scores in adult and
adolescent patients [8]. Unfortunately, frequent longitudinal
measurements of treatment burden in the same patient are
not generally available in ESCF. The dynamics of perceived
treatment burden over time, with and without changes in
treatment complexity, would be of considerable research interest
in future studies. In addition, as new therapies are developed and
implemented in the care of CF patients, attention must be paid to
whether continued additive therapies in the face of rising
complexity could negate the impact of new therapies because of
reduced adherence. Efforts to reduce complexity, via new
technologies or ease of administration, should be considered in
future CF drug development [16].
Our study is the first to evaluate the relationship between
treatment complexity at a site-level with health outcomes,
including lung function and QOL. Earlier analyses of ESCF
have identified associations between site-level markers of
aggressive care, such as frequency of visits, frequency of IV
and oral antibiotics, and frequency of cultures with site-level lung
Fig. 3. Treatment complexity scores by site-specific quartiles for CFQ-R treatment burden score.
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would be more aggressive with chronic therapies and have higher
average TCS. However, our site-level analysis did not show a
linear difference in average treatment complexity based on
average site lung function. In fact, the highest average site TCS
were at the highest and lower quartile sites for lung function. One
potential explanation for this observed relationship is that high
performing sites are more aggressive in terms of treatments, and
that low performing sites are recommending more therapies as
they have patient populations with increased disease severity.
Overall, our data suggests that treatment intensity at the site level
is likely more dependent on factors such as disease severity. Our
data does not allow us to investigate the impact of aggressive care
practices not captured in the TCS such as more frequent use
of oral antibiotics or lower thresholds for hospitalization. In
addition, frequency of routine maintenance visits and surveillance
may be more variable than the recommendations for chronic
medications and thus, may be more strongly associated with
average site-level patient outcomes. Interestingly, we did see an
association between site level nutritional status and TCS,
with higher average complexity at sites with better nutritional
outcomes. Perhaps these sites pay greater attention to nutrition,
resulting in higher prescriptions for non-respiratory therapies.
We also assessed patient-reported treatment burden using
the CFQ-R Treatment Burden scale. At the site level, we found
differences in average treatment complexity based on perceived
burden, with higher average treatment complexity in sites with
higher reported patient burden. These sites appear to care for
sicker patients, with an older average age and a lower averagelung function. Interestingly, these sites also appear to care for
more disadvantaged populations, with a greater proportion of
patients insured with Medicaid, a marker for socio-economic
disadvantage, at sites with higher reported treatment burden.
Socioeconomic disparities in health outcomes have been
described in other studies of CF patients, and our data suggests
that SES factors may also be contributing to perceptions of
treatment burden [17]. Overall, however, the relationship
between average treatment complexity and site-level reported
burden is in the expected direction, with higher complexity
scores at sites with patients reporting greater burden. This
suggests that monitoring patient perceived treatment burden
using instruments such as the CFQ-R has potential to aid
clinicians in their consideration of adding new medications,
particularly in clinical care centers that recommend highly
complex treatment regimens for their patients.
The major limitation of our analysis is that treatment data
was obtained from encounter-based, not patient-queried re-
ports. Thus, the treatment complexity score is a proxy for
recommended therapies and not necessarily the therapies used
by individual patients. Despite this limitation, the TCS could be
useful in evaluating overall treatment intensity as an aid to
decision-making about adding treatments to an existing complex
regimen. In conclusion, in a national cohort of CF patients, we
documented a substantial level of treatment complexity, which
was increasing over time. Future research is needed to understand
the associations between treatment complexity, adherence behav-
ior, and subsequent health outcomes. Future work is also needed
to reduce treatment burden and improve disease management and
467G.S. Sawicki et al. / Journal of Cystic Fibrosis 12 (2013) 461–467adherence, particularly in an era of novel, emerging CF therapies.
Finally, treatment complexity and patient-reported treatment
burden should be considered as outcome variables in comparative
effectiveness studies, which are needed to develop an evidence
base for clinicians and patients to make informed decisions about
adding new treatments to the regimen.
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